This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) ~~Use of the compounds of the following formula (I):~~ A method for the treatment of neurodegenerative diseases comprising administering an effective amount of a compound of formula (I):



(I)

wherein X represents OH, (C_{1-5}) alkoxy, NH_2, NH-C_{1-5}-alkyl, or N(C_{1-5} alkyl)$_2$;

R_1 is a residue derived from one of the amino acids Phe, Tyr, Trp, Pro, which each may be optionally substituted with one or more (C_{1-5}) alkoxy groups, (C_{1-5}) alkyl groups or halogen atoms, as well as Ala, Val, Leu or Ile;

R_2 is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, Leu ~~and~~ or Pro;

Y_1 and Y_2 independently from each other represent H or (C_{1-5}) alkyl;

R_3 and R_4 independently from each other represent H, OH, (C_{1-5}) alkyl or (C_{1-5}) alkoxy, provided that R_3 and R_4 are not both OH or (C_{1-5}) alkoxy; and

R_5 represents H, OH, (C_{1-5}) alkyl or (C_{1-5}) alkoxy;
or a pharmaceutically acceptable salt thereof~~;~~.
~~for the preparation of a medicament useful in the treatment of neurodegenerative diseases.~~

2. (currently amended) The ~~use~~ method according to claim 1, wherein x represents (C_{1-5}) alkoxy, NH_2, NH-C_{1-5}-alkyl, or N(C_{1-5} alkyl)$_2$.

3. (currently amended) The ~~use~~ method according to claim 1 or 2, wherein R_3 and R_4 independently from each other represent H, (C_{1-5}) alkyl or (C_{1-5}) alkoxy, provided that R_3 and R_4 are not (C_{1-5}) alkoxy.

4. (currently amended) The ~~use~~ method according to ~~any of the previous claims~~ claim 1, wherein R_5 represents H, (C_{1-5}) alkyl or (C_{1-5}) alkoxy.

5. (currently amended) The ~~use~~ method according to ~~any of the previous claims~~ claim 1, wherein the neurodegenerative disease is Alzheimer's disease.

6. (currently amended) The ~~use~~ method according to ~~any of the previous claims~~ claim 1, wherein the neurodegenerative disease is mild cognitive impairment.

7. (currently amended) The ~~use~~ method according to ~~any of the previous claims~~ claim 1, wherein R_1 is a residue which is derived from one of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted with a (C_{1-5}) alkoxy group, a (C_{1-5}) alkyl group or a halogen atom or which is derived from Ile.

8. (currently amended) The ~~use~~ method according to claim 7, wherein R_1 is a residue which is derived from Phe, which may optionally be substituted with a (C_{1-5}) alkoxy group, a (C_{1-5}) alkyl group or a halogen atom.

9. (currently amended) The ~~use~~ method according to ~~any of the previous claims~~ claim 1, wherein R_2 is a residue which is derived from the amino acid Gly or Ile.

10. (currently amended) The ~~use~~ method according to ~~any of the previous claims~~ claim 1, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide or a pharmaceutically acceptable salt thereof.

11. (currently amended) A pharmaceutical ~~Pharmaceutical~~ composition comprising compounds of the following formula (I):



(I)

wherein X represents OH, (C_{1-5}) alkoxy, NH_2, NH-C_{1-5}-alkyl, N(C_{1-5} alkyl)$_2$;

R_1 is a residue derived from one of the amino acids Phe, which each may be optionally substituted with one or more (C_{1-5}) alkoxy groups, (C_{1-5}) alkyl groups or halogen atoms;

R_2 is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, Leu and Pro;

Y_1 and Y_2 independently from each other represent H or (C_{1-5}) alkyl;

R_3 and R_4 independently from each other represent H, OH, (C_{1-5}) alkyl or (C_{1-5})alkoxy, provided that R_3 and R_4 are not both OH or (C_{1-5}) alkoxy; and

R_5 represents H, OH, (C_{1-5}) alkyl or (C_{1-5}) alkoxy;

or a pharmaceutically acceptable salt thereof ;

and pharmaceutically acceptable excipients.

12. (currently amended) The pharmaceutical ~~Pharmaceutical~~ composition according to claim 11, wherein x represents (C_{1-5}) alkoxy, NH_2, NH-C_{1-5} alkyl or N(C_{1-5} alkyl)$_2$.

13. (currently amended) The pharmaceutical composition according to claims 11 or 12, wherein R_2 is a residue which is derived from the amino acid Gly.

14. (currently amended) The pharmaceutical ~~Pharmaceutical~~ composition according to ~~claims~~ claim 11 ~~to 13~~, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucylphenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucylisoleucyl-prolineamide or a pharmaceutically acceptable salt thereof.

15. (canceled)